Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | SCD | O00767 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16160950 | 0.84 | SPHK1 (0.38) | SPHK1BRD4HSD11B2GPR119 | |
| SCHEMBL16160948 | 0.84 | SPHK1 (0.38) | SPHK1BRD4HSD11B2GPR119 | |
| SCHEMBL6186128 | 0.83 | CYP2D6 (0.42) | SPHK1BRD4HSD11B2LMNA | |
| SCHEMBL6186125 | 0.83 | CYP2D6 (0.42) | SPHK1BRD4HSD11B2LMNA | |
| SCHEMBL6748179 | 0.82 | SPHK1 (0.39) | SPHK1BRD4HSD11B2HTR1AGPR119 | |
| SCHEMBL6748180 | 0.82 | SPHK1 (0.39) | SPHK1BRD4HSD11B2HTR1AGPR119 | |
| SCHEMBL6751156 | 0.82 | SPHK1 (0.37) | SPHK1BRD4HSD11B2GPR119 | |
| SCHEMBL6750112 | 0.80 | SPHK1 (0.38) | SPHK1BRD4HSD11B2ALDH1A1GPR119 | |
| SCHEMBL6191324 | 0.80 | SPHK1 (0.38) | SPHK1BRD4HSD11B2ALDH1A1GPR119 | |
| SCHEMBL6746240 | 0.79 | SPHK1 (0.39) | SPHK1BRD4HSD11B2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242871-A1 | Novel arylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242871-A1 | Novel arylheteroalkylamine derivatives | CYP1A1, NOS3, NOS1 | SPHK1 1994/4885BRD4 3935/4885HSD11B2 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.